Julian D. Gillmore
机构：Alnylam Pharmaceuticals (United States), The Royal Free Hospital, Amyloidosis Foundation, Roland Hill (United Kingdom), University College London · ORCID：0000-0001-6174-9232
发表论文 570 篇 · 总被引 36078 次 · h-index 98
代表论文
- Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy (2025 · New England Journal of Medicine · 被引 31)
- Myocardial Amyloid Burden in Transthyretin Amyloidosis (2025 · Journal of the American College of Cardiology · 被引 11)
- Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM (2025 · Journal of the American College of Cardiology · 被引 9)
- New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System (2025 · Journal of Clinical Oncology · 被引 8)
- Artificial Intelligence-Based Echocardiographic Assessment for Monitoring Disease Progression in Transthyretin Cardiac Amyloidosis (2025 · European Journal of Heart Failure · 被引 7)
- Vutrisiran in Transthyretin Amyloidosis (2025 · JACC Advances · 被引 7)